PDCD1 and melanoma: Currently, ICIs that target cytotoxic T lymphocyte-associated antigen 4 (CTLA4) or programmed cell death protein 1 and its ligand (PD-1 and PD-L1) have been approved by the US Food and Drug Administration (FDA) for clinical application owing to their notable successes against melanoma and other solid malignancies (155–159).